

FREE NEWSLETTER

Free Daily FiercePharma Newsletter: Enter email Sign up About | View Sample | Privacy

FEATURES >> The most interesting logos in Pharma

Related Topics >> FDA | whistleblower | FDA update | Charles Grassley | Frank Torti

# Grassley tells FDA's Torti to back off staff

March 25, 2009 - 10:30am ET | By Calisha Myers

FDA Acting Commissioner Frank Torti's leaked email to agency employees regarding the agency's confidentiality policies has landed the commish in hot water with Sen. Charles Grassley, *Dow Jones* reports. Torti's March 13 email tells employees to keep propriety information to themselves. Included in that long list was privileged intra-agency and inter-agency communications, including emails, memos and letters. It also warns employees that disclosing information or documents "can result in disciplinary sanctions and/or individual criminal liability." At the time, Torti said that the memo was simply a reminder to employees to be mindful of confidential information, but Grassley's not buying it. In a letter sent out Tuesday, Grassley said he's concerned that Torti's memo "goes beyond legitimate privacy concerns and appears to run contrary to many statutes protecting executive branch communications with members of Congress."

It's illegal to silence whistleblowers, Grassley says, and he wants the Commissioner to send out another email clarifying that FDA employees have a right to provide information to Congress without fear of punishmen If the memo sent last week was intended to have a chilling effect on FDA employees who want to speak up about problems, then that memo is contrary to the President's call for open and transparent government, and the Acting Commissioner needs to set the record straight," Grassley said in a statement.

The FDA is never far from controversy, but it seems the mix of politics and science at the agency has more and more people ringing the reform bell lately. Staff scientists made headlines in January when nine of them wrote a letter to Obama asking for sweeping reform to clean up the "corrupt" FDA leadership and "antiscientist" culture. The group made headlines again just weeks later when they said they were being targeted for speaking out. The

scientists found themselves under criminal investigation for allegedly revealing confidential information regarding products under review.

- check out Grassley's release
- read the Dow Jones article

#### Related Articles:

FDA's Torti: Shut your flapping traps, stat FDA scientists: We're being targeted FDA scientists plea for agency reform Acting FDA chief promises science, not politics Sweep the FDA clean, Stupak says FDA scientist Torti moves to the helm FiercePharma
Tracy Staton, Editor
Maureen Martino, Editor
FIVE TOP STORIES
Is it time to lobby for Pfizer jobs?
Pharma women rank among world's most powerful
FDA slaps Apotex with import ban
Generic rivials push JSJ drug sales down 19%
GSK's \$3.28 bet on pandemic pays off
JOBS UPDATED DAILY

Free newsletter via e-mail
Your e-mail address
Sign Up For FiercePharma

RELATED STORIES

FDA scientist Torti moves to the helm Grassley, Dingell plan FDA

Grassley zeroes in on pharma whistleblowers

AZ chief: FDA needs 'a full set of teeth'

FDA may halt Avandia-Actos trial on safety concerns

TOOLS

Subscribe

Print

Comment

Contact Author

Reprint

1 of 3 9/8/10 4:36 PM



## **Get Your FREE FiercePharma Email Newsletter:**

Enter email Sign Me Up!

Comments (1) | Post a comment

MORE STORIES ABOUT whistleblower FDA update Charles Grassley Frank Torti FDA

Comments
By Anonymous   Posted 1:36pm   March 31, 2009
One wonders what sort of information is Torti trying to protect. The FDA is not supposed to be a business unless it is covertly operating as one and if so, that would completely illegal and should be thoroughly investigated. It seems likely that American consumers are compromised when the FDA operates like a business instead of a consumer protection agency and if so, it should be dissolved and the government start over on.
Post new comment
Your name:
Anonymous
E-mail:
The content of this field is kept private and will not be shown publicly.  Comment: *
More information about formatting options
This question is for testing whether you are a human visitor and to prevent automated spam submissions.  Type the two words:
Post comment

## PAID RESEARCH REPORTS

Cloud Computing Adoption In The APAC Life Sciences Industry

**Pharmaceutical Licensing Overview** 

Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina

**Pharmaceutical Key Trends 2010** 

Commercial Insight: Top 20 Oncology Therapy Brands in Australia

The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities

MORE RESEARCH REPORTS >>

 $Home \mid Subscribe \mid Advertise \mid Mobile \; Edition \mid RSS \mid Privacy \mid Site \; Map \mid List \; in \; Marketplace \mid Supplier \; in \; Marketplace$ 

a publication of FierceMarkets

2 of 3 9/8/10 4:36 PM

## THE FIERCEMARKETS NETWORK

THE FIERCEMARKETS NETWORK

FierceFinance | FierceFinaceIT | FierceComplianceIT | FierceHealthcare |
FierceHealthFinance | FierceHealthIT | Hospital Impact | FierceMobileHealthcare |
FierceHealthPayer | FiercePracticeManagement | FierceCIO | FierceCIO:TechWatch |
FierceContentManagement | FierceMobileIT | FierceGovernmentIT | FierceBiotech |
FierceBiotech Research | FiercePharma | FierceVaccines | FierceBiotechIT | FiercePharma
Manufacturing | FierceMedicalDevices | FierceDrugDelivery | FierceIPTV |
FierceOnlineVideo | FierceTelecom | FierceVoIP | FierceBroadbandWireless |
FierceDeveloper | FierceMobileContent | FierceWireless | FierceWireless:Europe |
FierceCable

© 2010 FierceMarkets. All rights reserved.

3 of 3 9/8/10 4:36 PM